Enigma Securities Expands Execution Services to Bitcoin Futures With CME Group Partnership

Enigma Securities, a crypto-focused financial institution, specialized in electronic execution services announced the expansion of its services to provide access for Bitcoin Futures and Options block trading, through a new partnership with CME Group.  By leveraging CME’s ClearPort platform, Enigma can facilitate block trading of CME Bitcoin derivatives for institutional market participants, providing its large network of traditional financial counterparties access to this nascent but rapidly growing asset class.

CME ClearPort is a comprehensive set of flexible clearing services for the global Over-The-Counter (OTC) market that clears transactions from 1,800 listed contracts over multiple asset classes. Clearing more than 300,000 contracts daily, CME ClearPort brings together more than 17,000 registered users worldwide, including commercial, banking and hedge fund firms, to Futures Commission Merchants (FCM’s) and clearing firms.

Recommended AI News: Picwell Launches Revolutionary Product Aimed At Taking The Guesswork Out Of Health Savings Accounts

“As the crypto market matures over time, institutional clients’ demand for risk management and liquidity alternatives away from spot products continues to grow at an accelerated pace,” said Jordan Ettedgui, Head of Trading at Enigma Securities.”Our core competency in equity derivatives naturally leads to a strong commitment to crypto derivatives execution services. We are very excited to  officially offer our clients access to Bitcoin Futures and Options through the world’s leading and most diverse derivatives marketplace.”

Recommended AI News: Vectra Expands Global Footprint Through Enriched Channel Partner Program, Training And Growth

Enigma Securities continues to improve the quality of its services and offerings for its institutional clients, who now have access to deep liquidity in CME-cleared Bitcoin derivatives.

Recommended AI News: Ardigen Enters Into Research Collaboration With CVC To Apply AI For Identification Of T-Cell Targets